MoneyWorks4Me

USFDA completes routine GMP inspection at Gland Pharma’s Visakhapatnam facility

02 Sep 2026 Evaluate

The United States Food and Drug Administration (USFDA) has completed a routine Good Manufacturing Practice (GMP) inspection at Gland Pharma’s VSEZ Sterile Oncology Formulations Facility and API Facility at Visakhapatnam. The inspection, conducted from August 24 to September 1, 2026, was concluded with ZERO Form 483 Observations.

Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in many countries. 


Gland Pharma Share Price

2933.55 28.70 (0.99%)
04-Sep-2026 14:57 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1901.00
Dr. Reddys Labs. 1157.40
Cipla 1380.45
Lupin 2106.55
Zydus Lifesciences 1126.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: